The latest price target for Agios Pharmaceuticals (NASDAQ:AGIO) was reported by RBC Capital on August 2, 2024. The analyst firm set a price target for $55.00 expecting AGIO to rise to within 12 months (a possible 20.77% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Agios Pharmaceuticals (NASDAQ:AGIO) was provided by RBC Capital, and Agios Pharmaceuticals maintained their outperform rating.

The last upgrade for Agios Pharmaceuticals Inc happened on November 17, 2022 when Goldman Sachs raised their price target to $32. Goldman Sachs previously had a sell for Agios Pharmaceuticals Inc.

There is no last downgrade for Agios Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agios Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agios Pharmaceuticals was filed on August 2, 2024 so you should expect the next rating to be made available sometime around August 2, 2025.

While ratings are subjective and will change, the latest Agios Pharmaceuticals (AGIO) rating was a maintained with a price target of $53.00 to $55.00. The current price Agios Pharmaceuticals (AGIO) is trading at is $45.54, which is out of the analyst’s predicted range.